M. Krokowski et al., ANTI-BOVINE SERUM-ALBUMIN ANTIBODIES - GENETIC-HETEROGENEITY AND CLINICAL RELEVANCE IN ADULT-ONSET IDDM, Diabetes care, 18(2), 1995, pp. 170-173
Citations number
13
Categorie Soggetti
Endocrynology & Metabolism","Medicine, General & Internal
OBJECTIVE- To evaluate the prevalence of anti-bovine serum albumin (BS
A) antibodies in patients with adult-onset insulin-dependent diabetes
mellitus (IDDM) and investigate a possible link between their presence
and genetic susceptibility or resistance determined by human leukocyt
e antigen (HLA) complex. RESEARCH DESIGN AND METHODS- Sera from 60 rec
ent-onset diabetic patients, 5 prediabetic subjects, and 102 healthy c
ontrol subjects were tested using a radioimmunoprecipitation assay. HL
A-DRB and -DQB alleles were determined by means of allele-specific oli
gonucleotide typing. Islet cell antibodies (ICAs) were assayed by indi
rect immunofluorescence. RESULTS- Levels of anti-BSA antibodies were s
ignificantly higher in IDDM patients (18.1 +/- 3.5%, n = 60) than in h
ealthy control subjects (7.5 +/- 1.2%, n = 102) (P < 0.001), but in on
ly 16.6% of IDDM patients (10 of 60) were the titers above the 95th pe
rcentile of control values. Anti-BSA antibody titers were higher in HL
A-DR3 and/or -DR4 patients (23.4 +/- 4.9%, n = 41) compared with DR3 a
nd/or DR4 control subjects (3.1 +/- 1.0%, n = 10) (P < 0.001). DR3 IDD
M patients showed higher levels of anti-BSA antibodies (26.3 +/- 6.3%,
n = 30) than non-DR3 patients (9.9 +/- 2.6%, n = 30) (P < 0.01) and h
ealthy control subjects. Only two out of five prediabetic subjects had
significant anti-BSA levels before clinical onset of diabetes. CONCLU
SIONS- Our data confirm that antibodies to BSA are present in adult-on
set IDDM patients, particularly in HLA-DR3-positive patients. However,
the prevalence of anti-BSA antibodies was lower than previously repor
ted in children, and there was a considerable overlap with healthy con
trol subjects. Only two out of the five prediabetic patients demonstra
ted anti-BSA antibodies. Taken together, these results do not bring st
rong support to the clinical usefulness of anti-BSA antibodies as a re
levant marker in diabetes prediction or diagnosis.